{"entity":{"id":"nct06846606","kind":"trial","name":"Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS","aka":[],"tldr":"A phase 1 trial of AUTX-703 run by Auron Therapeutics, Inc., now recruiting.","summary":"Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS is a phase 1 interventional study registered as NCT06846606 by Auron Therapeutics, Inc., with 69 participants planned, started 2025-05-01. Conditions recorded: Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). Interventions recorded: AUTX-703.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06846606","url":"https://clinicaltrials.gov/study/NCT06846606"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds"],"sections":[],"technologies":[],"targets":[],"drugs":["autx-703"],"companies":["auron-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06846606","phase":"1","setting":"A Phase 1 Study of AUTX-703 in Participants With Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes","sponsor":"Auron Therapeutics, Inc.","enrolled":69,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06846606/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"drug":[{"id":"autx-703","kind":"drug","name":"AUTX-703","route":"/drugs/autx-703/"}],"company":[{"id":"auron-therapeutics","kind":"company","name":"Auron Therapeutics","route":"/companies/auron-therapeutics/"}]}}